Journal: bioRxiv

Article Title: HLA-G engineering reprograms CAR-T cells with an immune privilege

doi: 10.64898/2026.05.10.723228

Figure Lengend Snippet: a , Timeline of the first animal study using NOG-hIL-15 (NOG15) mouse ( s.c. , i.p. and i.v. stand for subcutaneous, intraperitoneal and intravenous, respectively). b , Table showing specific amount of cells used for three dosings (see a ) in the humanized animals. c , Human leukocyte antigen (HLA) haplotype information for PBMC donor 416C (green) and 202C (magenta). Note that 416C is HLA-A2-positive. d - f , Data from the humanized mouse study showing tumor volume ( d ), the percent of human CD45 (hCD45) positive cells over total CD45 + cells (hCD45 + plus mCD45 + ) ( e ), and the amount of human hCD45 + /hCD3 - /hCD56 + NK cells ( f ) (see for flow cytometric gating strategy and percent/events conversion). A dotted line in d indicates that mice were supposed to be euthanized when the tumor volume was larger than 3000 mm 3 . Note that mouse 18019 was not euthanized on day 17 hoping the injected CAR-T cells might reduce tumor volume below 3000 mm 3 after the second dosing. A dotted line in e indicates a 20% hCD45 reconstitution cutoff. g , Flow cytometric analysis for hCD45 + cells in peripheral blood collected from mouse 18025 and 18023 on day 20 and 24. See also .

Article Snippet: 6-8 week old female NOD.Cg- Prkdc scid IL2rg tm1Sug Tg(CMV-IL2/IL15)1-1Jic/JicCrl mice, or NOG-hIL-15 (Charles River, Beijing) in short, were allowed to acclimate to the animal facility at the CRO for 5-7 days in a group-housing setting with 2–3 mice per cage in a reverse 12 hour light/dark cycle with ad libitum access to food and water.

Techniques: Injection